Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
| ▸ | REN | P00797 | 3/20 | 0.38 |
| ▸ | CDK9 | P50750 | 8/20 | 0.36 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 2/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.33 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13229308 | 0.89 | REN (0.41) | SLC22A12RENCDK9TRPM5TAAR1 | |
| SCHEMBL13229394 | 0.88 | SLC22A12 (0.40) | SLC22A12CDK9TRPM5TAAR1BRD4 | |
| SCHEMBL13229072 | 0.88 | REN (0.36) | SLC22A12RENCDK9TRPM5TAAR1 | |
| SCHEMBL13229395 | 0.87 | SLC22A12 (0.39) | SLC22A12CDK9TRPM5TAAR1BRD4 | |
| SCHEMBL13229319 | 0.85 | REN (0.38) | SLC22A12RENCDK9CYP3A4 | |
| SCHEMBL13229397 | 0.85 | CDK9 (0.40) | SLC22A12RENCDK9TRPM5TAAR1 | |
| SCHEMBL14117490 | 0.84 | TNIK (0.37) | SLC22A12CDK9TRPM5TAAR1TRPV1 | |
| SCHEMBL13229405 | 0.84 | HDAC1 (0.41) | SLC22A12CDK9TRPM5TAAR1TRPV1 | |
| SCHEMBL13229092 | 0.84 | PRKCQ (0.39) | SLC22A12RENCDK9TRPM5BRD4 | |
| SCHEMBL13229407 | 0.84 | HDAC1 (0.43) | SLC22A12CDK9TRPM5TAAR1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501747-B2 | Functionally selective alpha2C adrenoreceptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501747-B2 | Functionally selective alpha2C adrenoreceptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20100197562-A1 | FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION AND PHARMACOPEIA, LLC (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100197562-A1 | FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION AND PHARMACOPEIA, LLC (US) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197562-A1 | FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | ADRA2C, ADRB2, ADRB3 | SLC22A12 2838/4885REN 117/4885CDK9 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.